Pharvaris' oral deucrictibant cuts hereditary angioedema attacks by 83% in pivotal Phase 3

Pharvaris announced positive topline results on 8 September 2026 from CHAPTER-3, a pivotal late-stage trial of its oral drug deucrictibant as a preventive treatment for hereditary angioedema (HAE) — a rare inherited disease that causes sudden, painful and sometimes life-threatening swelling attacks in the skin, gut and airway.